Preview Newsletter
XARELTO Media Monitoring – Week of 4-29-16
-
Xarelto Bleeding Lawsuit Filings Transferred And Consolidated By JPML Under U.S. District Judge Eldon Fallon
Apr 29, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the transfer and consolidation of all federally-filed Xarelto related lawsuits by the U.S. Judicial Panel on Multidistrict Litigation. The cases are able to be filed, forming MDL number 2592, due to the fact that they were filed against the same defendants (Bayer and Janssen) and that they contain strikingly similar plaintiff allegations. -
Xarelto Lawsuit Plaintiffs Note Allegation Similarities To Pradaxa Lawsuits, Gain Encouragement
Apr 28, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the resemblence of arguments in Xarelto lawsuits to that of older Pradaxa lawsuits, which has provided current plaintiffs with hope as they pursue what they believe to be justice. Xarelto lawsuit filings have mounted within the last five years, and have come to number in the thousands just as Pradaxa lawsuits did some time ago. Today, federally-filed Xarelto complaints were transferred and consolidated to a single court, forming multidistrict litigation number 2592 in Eastern Louisiana. These cases reportedly number over 2,800 at this time, and are joined by another group of more than 620 cases which were consolidated to form a mass tort program in Philadelphia, Pennsylvania by the Court of Common Pleas. Those closely involved in each grouping expect that these numbers will continue to grow as time moves forward. -
Xarelto Lawsuit News Draws Attention To BMJ Study Noting Possible Twofold Increased Risk Of GI Bleeds
Apr 28, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the concerning results of two studies which appear to link anticoagulant Xarelto to an increased risk for the development of dangerous bleeding events among patients. As Xarelto lawsuit filings in Philadelphia and Louisiana continue to mount, and public attention turns to the current multidistrict litigation and mass tort program, many are becoming concerned over the potential severe bleeding side effects which have been connected to the drug through adverse event reports and studies. Plaintiffs who have filed lawsuits in reference to the new-generation blood thinner gain support from these 2015 studies, which seem aligned with their current allegations. -
South Florida Widow Files Xarelto Lawsuit Alleging Drug Caused Her Husbands Fatal Bleed
Apr 28, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of another lawsuit which was filed against Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation) referencing their new-generation blood-thinning drug Xarelto. The plaintiff in this case alleges that Xarelto use caused the death of her husband. The widow has filed a wrongful death suit which was initially listed under case number 9:14-cv-80831 in a Southern Florida court but was later transferred to the Eastern District of Louisiana to be consolidated with thousands of other similar lawsuits forming multidistrict litigation No. 2592. The MDL is being overseen at this time by the Honorable Judge Eldon Fallon. -
Xarelto Lawsuit Plaintiffs Note New York Times Article Reporting Possible Error During Xarelto Clinical Studies
Apr 22, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com comments on reports from a New York Times article which announced the U.S. Food and Drug Administration’s current investigation into whether a recalled, potentially faulty blood-testing device may have impacted Xarelto clinical trial results and therefore led to Xarelto’s premature approval. -
Louisiana Xarelto Lawsuit Plaintiff Alleges Blood-Thinning Drug Caused Fatal Bleed Of Grandmother
Apr 22, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit which has been filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a division of corporate giant Johnson & Johnson). The lawsuit was filed in reference to new-generation anticoagulant drug Xarelto and was filed by a granddaughter on behalf of her deceased grandmother. -
Family Of Alabama Woman Files Xarelto Wrongful Death Lawsuit
Apr 25, 2016 | Righting Injustice
By Jennifer Walker-Journey
The family of an Alabama woman is suing Johnson & Johnson’s Janssen Pharmaceuticals and Bayer Healthcare, and their related companies, over claims that the companies’ blood thinner Xarelto caused injuries that contributed to her death. -
Xarelto Lawsuit Plaintiffs Await Results Of European Regulator Investigation Into Xarelto Clinical Trial Results
Apr 26, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on an ongoing investigation conducted by European regulators concerning the results of Xarelto clinical trials. The investigation comes after increasing controversial claims surrounding the new-generation blood thinner, and its 2011 approval by the U.S. Food and Drug Administration. Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals are also facing thousands of lawsuits concerning the drug at this time, involving plaintiffs from across the nation who similarly allege that use of the anticoagulant drug can place patients at increased risk for the development of severe and dangerous bleeding events. -
Xarelto Lawsuit Filing Numbers Reportedly Rising In Both United States And Canada
Apr 26, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on Xarelto lawsuit filings, which have been regularly growing in number across the United States and Canada. Reports state that a lawsuit referencing Xarelto had been filed last February in Calgary, Canada and that another lawsuit filing is anticipated in Ontario. Plaintiffs in the U.S. have indicated that seeing the filings in Canada as well help to cement their allegations and prove that Canadian patients are also claiming that the drug can place users at increased risk for severe bleeding episodes. -
Xarelto Lawsuit Plaintiffs See Clinical Trial Results Investigated After Discovery Of Potentially Defective Device
Apr 26, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com comments on reports from Reuters with more details on current Xarelto lawsuits. Currently, it has been indicated that both U.S. and European drug regulators are investigating to determine whether a defective blood clotting medical device used during Xarelto clinical trials could have impacted the outcome of the results gathered. It has been indicated that the results may have been impacted in Xarelto’s favor, and could have led to a premature FDA-approval of the new-generation blood thinner, manufactured by Bayer AG and Johnson & Johnson subsidiary Janssen Pharmaceuticals. -
Xarelto Lawsuit Plaintiff Alleges That Anticoagulant Caused Life-Threatening Internal Bleed
Apr 27, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of a lawsuit which has been filed against Xarelto manufacturers Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) and Bayer Healthcare. The complaint was initially filed in the Eastern District of New York under case number 1:14-cv-04524. It was filed by a plaintiff from Texas who claims that new-generation blood thinner Xarelto’s manufacturers neglected to inform consumers and medical professionals of the dangerous side effects which she now links to use of their drug. -
Ohio Xarelto Lawsuit Plaintiffs Claim Bayer And Janssen Are Responsible For Life-Threatening Injuries Endured By Patient
Apr 27, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of a lawsuit which has been filed against Bayer Healthcare and Janssen Pharmaceuticals (a subsidiary of parent company Johnson & Johnson). The lawsuit discusses Xarelto the new-generation, blood-thinning drug they manufacture. It was filed by a married couple from Ohio who together claim that the use of the anticoagulant caused the wife to endure a life-threatening internal bleed. The couple is seeking more than $150,000 in compensation to assist with current and future medical bills, as they note that the side effects from the bleed continue to impact the woman today, and will require medical care for a long-term period of time. -
NBA All-Star Chris Bosh Draws Public Attention To Blood Clot Dangers As Xarelto Lawsuit Numbers Increase
Apr 27, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com comments on a recent news release from Business Insider which indicated that NBA-All Star Chris Bosh of the Miami Heat is now struggling with another blood clot scare. Details regarding his current condition and specifics of his future basketball career plans have yet to be released, and as the article noted, “no determination will be made about his playing status until he goes through more tests and evaluation.” This information was attributed to ‘a person with knowledge’. -
Xarelto Lawsuit Plaintiffs Allege 4 Years Without An Available Antidote Is Negligent
Apr 26, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com comments on a common point of concern for plaintiffs involved in Xarelto bleeding lawsuits. Thousands of plaintiffs who have filed suit against the new-generation anticoagulant allege that the drug’s manufacturers, Bayer AG, and Janssen Pharmaceuticals showed severe negligence by neglecting to release the blood thinner to market with a corresponding antidote. -
Xarelto Risk of Bleeding
Apr 29, 2016 | Top Class Actions
By Tamara Burns
Xarelto (rivaroxaban) is a medication used to prevent clots in the blood, otherwise known as an anticoagulant or blood thinner. It has been on the market since 2008 and is manufactured by Bayer. -
Xarelto Lawsuit
Apr 22, 2016 | ClassAction.com
Approved by the U.S. Food and Drug Administration (FDA) in 2011, Xarelto is indicated to reduce the risk of strokes, deep vein thrombosis (DVT), pulmonary embolism (PE), and blood clots. Xarelto has been promoted as superior to older types of blood thinners but may in fact be more dangerous because, unlike older products, it can cause bleeding that cannot be stopped, even by a doctor. The legal team at ClassAction.com is filing lawsuits on behalf of injures Xarelto users and their loved ones. -
Week Adjourned: 4.22.16 – Xarelto, Natural Sunscreen, NFL Concussions
Apr 22, 2016 | LawyersandSettlements.com
By Lucy C
Xarelto Lawsuits Head North. Bayer Inc, is facing a Xarelto class action lawsuit filed in Canada—in Calgary to be precise—alleging its blood thinner is linked to dozens of deaths. The lead plaintiff in this class action alleges that the anticoagulant drug caused her to suffer from an uncontrollable bleeding event which nearly led her to cardiac arrest. Sadly, this lawsuit has a familiar ring to it. -
Xarelto Litigation Scheduling Order Sets Injury Cases in Motion
Apr 25, 2016 | Lieff Cabraser Heimann & Bernstein
By Lieff Cabraser
On April 21, 2016, Judge Eldon E. Fallon, the federal judge supervising and overseeing the centralized litigation against Janssen, Johnson & Johnson and Bayer over Xarelto, issued an order scheduling the depositions of plaintiffs and defense witnesses. The court is overseeing the discovery necessary to develop several “bellwether” trials in order to evaluate the strength and weaknesses of the cases brought against the pharmaceutical giants and to determine the values of certain harms and injuries. -
California Man Blames Xarelto for Subdural Hematoma
Apr 26, 2016 | The Legal Examiner
By Kendra Goldhirsch
In December 2014, all federally filed Xarelto lawsuits were consolidated into the Eastern District of Louisiana for pre-trial proceedings. Since then, the court has seen a steady increase in the number of cases there. Another new lawsuit joined the MDL on March 16, 2016. The plaintiff is a resident of California, and claims that after using Xarelto, he suffered serious injuries. He seeks damages in excess of $75,000. -
More Than 4,500 Xarelto Lawsuits Consolidated
Apr 27, 2016 | LawyersandSettlements.com
By Heidi Turner
The number of Xarelto lawsuits consolidated for pretrial proceedings sits at more than 4,500, and a lawsuit alleging patients suffered from Xarelto side effects has now been filed in Canada. Meanwhile, the New York Times (3/1/16) reports that some researchers are concerned about data apparently left out of a vital Xarelto study. Whether more Xarelto lawsuits are on the way remains to be seen. -
Xarelto Attorneys
Apr 27, 2016 | Isaacs & Isaacs
If you or somebody you love was injured from taking the anticoagulant Xarelto you need to talk to an Isaacs & Isaacs Xarelto Lawsuit lawyer immediately. We have a 99% success rate in winning fair and just compensation for our clients. We serve people in Kentucky, Indiana & Ohio. Call 800-800-8888 now to speak with an experienced Xarelto lawyer. Our team is standing by 24/7 to help folks who have been hurt by this dangerous drug.
Full Text of Stories Below
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
-
Apr 29, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the transfer and consolidation of all federally-filed Xarelto related lawsuits by the U.S. Judicial Panel on Multidistrict Litigation. The cases are able to be filed, forming MDL number 2592, due to the fact that they were filed against the same defendants (Bayer and Janssen) and that they contain strikingly similar plaintiff allegations.
The complaints were transferred to a single court in Eastern Louisiana and are now being overseen by the Honorable U.S. District Judge Eldon E. Fallon. The consolidation was issued on December 12, 2015, generating the transfer of these federal cases, and helping to “fast track” the litigation process by avoiding duplicative discovery or different rulings from multiple judges. It will also help to conserve resources for everyone involved.
In just five year’s time, Xarelto lawsuits have grown to number more than 3,400, and have been consolidated to form two major groupings. Lawsuits consolidated in the MDL number over 2,800 and are expected to continue to rise. In addition, these lawsuits are joined by more than 620 other cases which were consolidated to form a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania. Plaintiffs involved in these lawsuits synonymously allege that use of new-generation blood-thinning drug Xarelto places users at increased risk for the development of sudden bleeding events, some of which can be life-threatening and prove fatal.
The MDL consolidation decision came in response to a request from a group of plaintiffs submitted in October 2015. The request asked that the JPML centralize the cases to help litigation run more smoothly and efficiently. Initially, plaintiffs asked that the involved cases be centralized in the Southern District of Illinois. The defendants contested this request, however, arguing that the cases should be centralized in New Jersey, where their headquarters were located. Defendant Janssen Pharmaceuticals is a division of corporate giant Johnson & Johnson.
After a hearing session which was held on December 4, 2015, the JPML noted, “In our judgement, the considerable growth in the litigation over the past few months demonstrates that informal coordination is not practical.” Additionally, they stated that they had determined the lawsuits would be overseen by the Honorable Judge Eldon Fallon, and explained, “Judge Eldon E. Fallon, who presides over three potential tag-along (Xarelto) actions, is an experienced transferee judge with the willingness and ability to manage this litigation efficiently. He is well-versed in multidistrict litigation, and we are confident he will steer this matter on a prudent course.”
As the plaintiffs involved in Xarelto lawsuits anxiously await trial dates, many anticipate that filing numbers will continue to steadily grow. At this time, Attorney Joseph Osborne is working to help other patients who have used Xarelto and who feel that the blood thinner has negatively affected their health. He wants to help ensure that all affected patients are provided with an opportunity to fully explore their legal rights, as they may be entitled to significant compensation attained through legal action. To assist those who wish to investigate their options further, Attorney Osborne is now offering complimentary legal consultations to affected parties.
To request further Xarelto lawsuit information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.ktvn.com/story/31850611/xarelto-bleeding-lawsuit-filings-transferred-and-consolidated-by-jpml-under-us-district-judge-eldon-fallon
-
Xarelto Lawsuit Plaintiffs Note Allegation Similarities To Pradaxa Lawsuits, Gain Encouragement
Apr 28, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the resemblence of arguments in Xarelto lawsuits to that of older Pradaxa lawsuits, which has provided current plaintiffs with hope as they pursue what they believe to be justice. Xarelto lawsuit filings have mounted within the last five years, and have come to number in the thousands just as Pradaxa lawsuits did some time ago. Today, federally-filed Xarelto complaints were transferred and consolidated to a single court, forming multidistrict litigation number 2592 in Eastern Louisiana. These cases reportedly number over 2,800 at this time, and are joined by another group of more than 620 cases which were consolidated to form a mass tort program in Philadelphia, Pennsylvania by the Court of Common Pleas. Those closely involved in each grouping expect that these numbers will continue to grow as time moves forward.
Xarelto lawsuits consolidated in MDL 2592 are being overseen by the Honorable Judge Eldon Fallon, and have been filed against defendants Bayer AG and Janssen Pharmaceuticals, (a subdivision of Johnson & Johnson) who manufacture the new-generation blood-thinning drug.
Judge Fallon has requested that involved parties prepare for a series of 4 bellwether trials to be heard by juries in early 2017 regarding the cases at hand. These bellwether trials are designed to give those involved an idea of how juries might respond to certain pieces of evidence and testimony. The plaintiffs who have filed lawsuits in the Xarelto MDL all similarly allege that the anticoagulant drug can cause sudden and dangerous bleeding events. In some cases, as reported by several plaintiffs filing suit on behalf of loved ones, these bleeding episodes have been fatal.
Pradaxa is very similar to Xarelto in that it is a new-generation blood thinner. This blood thinner, however, was manufactured by Boehringer Ingelheim in October of 2010. As is the current case with Xarelto, shortly after Pradaxa’s release to market, the drug was surrounded by more than 3,500 reports of severe adverse events among patients. Over 750 of these reports involved death. Pradaxa soon became the topic of more than 4,000 lawsuits. The evening before Pradaxa trials were set to begin, however, manufacturer Boehringer Ingelheim settled the lawsuits by agreeing to pay $650 million in compensation to plaintiffs.
Today, Xarelto lawsuit plaintiffs say that this decision gives them additional hope as their cases more closer toward trial dates. They await potential settlement talks from Bayer and Janssen, but have not yet gotten any indications that this will take place. As those involved prepare for early 2017 bellwether trial dates, Attorney Joseph Osborne has been working to help other patients who feel that they have been negatively affected after using Xarelto. He wants to ensure that these patients will be given the opportunity to evaluate their legal rights in the matter, as they may be entitled to significant compensation. To better assist these individuals, Attorney Osborne is currently offering free Xarelto consultations.
To ask questions, or to request additional Xarelto lawsuit information, please contact Attorney Joseph Osborne by calling (866) 425-8902.
http://www.cbs19.tv/story/31845715/xarelto-lawsuit-plaintiffs-note-allegation-similarities-to-pradaxa-lawsuits-gain-encouragement
-
Apr 28, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the concerning results of two studies which appear to link anticoagulant Xarelto to an increased risk for the development of dangerous bleeding events among patients. As Xarelto lawsuit filings in Philadelphia and Louisiana continue to mount, and public attention turns to the current multidistrict litigation and mass tort program, many are becoming concerned over the potential severe bleeding side effects which have been connected to the drug through adverse event reports and studies. Plaintiffs who have filed lawsuits in reference to the new-generation blood thinner gain support from these 2015 studies, which seem aligned with their current allegations.
This first notable study conducted in reference to the blood-thinning drug was published in BMJ’s April 2015 issue, and it noted that patients who use Xarelto (rivaroxaban) could be as much as doubling their risk of the likelihood of development of gastrointestinal bleeds when compared with those who take traditional blood-thinning drug warfarin. At the conclusion of their study, the researchers stated, “…we cannot rule out…a more than twofold higher risk of bleeding with rivaroxaban compared with warfarin.”
Another Xarelto-based study published by JAMA Ophthalmology on June 25, 2015 indicated that researchers had discovered a link between the use of rivaroxaban (Xarelto’s generic form) and an elevated risk of the development of eye bleeds called spontaneous vitreous hemorrhage. These researchers stated, “The risk of hemorrhage may be particularly elevated during the transition period when patients are switched from baseline anticoagulant to rivaroxaban therapy and are taking both anticoagulants simultaneously.”
The drug has been given two “black box” warnings from the FDA, which are the most severe product warnings the FDA is able to give before removing a drug completely from the market. In the five years since its 2011 release, Xarelto has become associated with more than 3,400 lawsuits filed across the nation. The complaints have been consolidated to form two main groupings. Over 2,800 Xarelto lawsuits which were federally-filed have been formed into MDL 2592 in Eastern Louisiana, while over 620 other Xarelto lawsuits have been formed into a mass tort program in Philadelphia, Pennsylvania by the Court of Common Pleas.
Attorney Joseph Osborne understands well the potentially devastating and even deadly effects of uncontrollable bleeding events. He is currently working to help other patients who have used Xarelto and who believe that the blood thinner has negatively affected their health. He wants to encourage these individuals to take advantage of the opportunity to investigate their legal rights in full, as they may be entitled to substantial compensation. To better assist those wishing to explore their options further, Attorney Osborne is also currently offering free legal consultations for qualified parties.
To request more Xarelto bleeding lawsuit information, or to ask questions, contact Attorney Joseph Osborne by calling (866) 425-8902.
http://www.kxnet.com/story/31845913/xarelto-lawsuit-news-draws-attention-to-bmj-study-noting-possible-twofold-increased-risk-of-gi-bleeds
-
South Florida Widow Files Xarelto Lawsuit Alleging Drug Caused Her Husbands Fatal Bleed
Apr 28, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of another lawsuit which was filed against Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation) referencing their new-generation blood-thinning drug Xarelto. The plaintiff in this case alleges that Xarelto use caused the death of her husband. The widow has filed a wrongful death suit which was initially listed under case number 9:14-cv-80831 in a Southern Florida court but was later transferred to the Eastern District of Louisiana to be consolidated with thousands of other similar lawsuits forming multidistrict litigation No. 2592. The MDL is being overseen at this time by the Honorable Judge Eldon Fallon.
Further details from within the lawsuit state that the widow claims that Xarelto manufacturers neglected to properly warn medical professionals and patients about potentially serious risks surrounding their product, such as sudden bleeding episodes and other adverse events she now connects to use of their product. The widow alleges that the anticoagulant caused her husband’s death, which happened when he suffered from an unexpected and uncontrollable internal bleeding event. Due to the Xarelto in his system, the woman reports, doctors were unable to clot his blood.
The woman goes on to explain that her husband was given a prescription for Xarelto as a treatment for his atrial fibrillation condition. The drug was intended to stop him from experiencing strokes, however, while the man was taking the drug, he instead suffered a subdural hemorrhage (or brain bleed), which caused him to ultimately pass away after doctors could not stop the bleed.
Unfortunately, this widow is not alone in her lawsuit claims. In just five year’s time, Xarelto has become the subject of over 3,400 lawsuits which have been formed into two main groupings. Over 2,800 federally-filed lawsuits have been transferred by the JPML to form MDL 2592 in Eastern Louisiana while more than 620 others have been formed into a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania. Involved plaintiffs share strikingly similar allegations that the drug places users at increased risk of severe and potentially life-threatening bleeding events.
As those involved anxiously await their day at trial, Attorney Joseph Osborne is working to help other patients who have used Xarelto and who believe the drug has negatively impacted their health. He hopes to ensure that all affected patients will be provided with the important opportunity to investigate their legal rights in the matter, as they may be entitled to significant compensation. To assist those wishing to further explore their options at this time, Attorney Osborne is offering complimentary legal consultations for qualified parties.
To request additional information, or to ask questions, contact Attorney Joseph Osborne at your convenience by calling (866) 425-8902.
http://www.keyc.com/story/31845525/south-florida-widow-files-xarelto-lawsuit-alleging-drug-caused-her-husbands-fatal-bleed
-
Apr 22, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com comments on reports from a New York Times article which announced the U.S. Food and Drug Administration’s current investigation into whether a recalled, potentially faulty blood-testing device may have impacted Xarelto clinical trial results and therefore led to Xarelto’s premature approval.
Xarelto is manufactured by Johnson & Johnson’s subsidiary company Janssen Pharmaceuticals and Bayer AG. The drug is a new-generation anticoagulant which gained FDA approval in 2011, and was released to the market for public use. Initially, Xarelto was very popular, offering users freedoms that traditional blood thinners had not been able to. The drug has reportedly made billions of dollars for the manufacturers. In just five years time, however, Xarelto has been linked to sudden, dangerous bleeding events among patients, and to over 3,400 lawsuits from across the nation.
These 3,400 lawsuits have been filed by plaintiffs who commonly allege that the blood thinner is significantly dangerous. Over 2,800 of the cases have been federally-filed and were transferred and consolidated to a single court in Eastern Louisiana by the U.S. Judicial Panel on Multidistrict Litigation. In addition, over 620 other Xarelto lawsuits have been consolidated in Philadelphia, Pennsylvania by the Court of Common Pleas, forming a mass tort program.
New controversies have erupted surrounding the drug now that the New York Timeshas indicated that the FDA is now asking Johnson & Johnson, “detailed questions about whether there was evidence that the device was malfunctioning while the trial was underway, according to a legal brief filed in federal court on Monday by lawyers for patients and their families who say they were injured by the drug. The lawyers also cited internal company documents that they said showed doctors were complaining to the trial leadership during the course of the study.”
Questions over the accuracy of clinical trial results have been discussed since last fall when both Johnson & Johnson (Janssen) and Bayer, were said to have “notified regulators that the device that was used in the trial had been recalled in 2014 because it was understating patients’ risk of bleeding.” The medical device in question is known as an INRatio, and is used to measure clotting rates, and help evaluate how many bleeding episodes or strokes were experienced by patients taking Xarelto compared to those who were taking warfarin, a traditional blood thinner.
The New York Times also indicated that at this time, “Regulators are looking at whether the malfunctioning device might have led doctors to give patients the wrong dose of warfarin, which could have led to additional bleeding episodes and given an unfair advantage to Xarelto.”
As those closely involved anxiously await the results of these investigations, Attorney Joseph Osborne is working to help other patients who have used Xarelto and who feel that it has negatively impacted their health. He hopes to ensure that all affected patients will be given the important opportunity to investigate their legal rights in the matter. Patients could be entitled to substantial compensation gained through legal action. To help those wishing to explore their legal options fully, Attorney Osborne is now offering complimentary Xarelto consultations to qualified parties.
To obtain more information, or to ask questions, please contact Joseph Osborne, Esq. at (866) 425-8902.
http://www.digitaljournal.com/pr/2912800
-
Louisiana Xarelto Lawsuit Plaintiff Alleges Blood-Thinning Drug Caused Fatal Bleed Of Grandmother
Apr 22, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit which has been filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a division of corporate giant Johnson & Johnson). The lawsuit was filed in reference to new-generation anticoagulant drug Xarelto and was filed by a granddaughter on behalf of her deceased grandmother.
The granddaughter alleges that her grandmother passed away after experiencing a sudden and severe bleeding episode while using Xarelto. Further lawsuit details note that in September of 2014, the grandmother obtained a prescription for the blood thinner from her doctor. It was given in order to treat her deep vein thrombosis (DVT) and prevent blood clot complications. Just two months later, in November of 2014, the grandmother developed an intracranial bleed (brain bleed) while Xarelto was actively in her system. Physicians reportedly indicated that the bleed was “irreversible and fatal,” and it caused the woman to die.
The granddaughter now alleges that Xarelto was the cause of her grandmother’s bleed, and therefore her death as well. She notes that doctors could not clot the woman’s blood and stop the bleed, because they were unable to counter the drug’s effects. The plaintiff additionally indicates that when determining which blood thinner her grandmother should take, they had made note of several Xarelto advertisements which promoted the positive aspects of the drug without adequately warning of the dangerous potential side effects. She stated that the marketing tactics of the defendants, “overstated the efficacy of Xarelto with respect to preventing stroke and systemic embolism.”
The lawsuit was filed in Eastern Louisiana under case number 2:15-cv-05874, and has since been consolidated to form multidistrict litigation number 2592 by the U.S. Judicial Panel on Multidistrict Litigation. This MDL includes more than 2,800 other similar Xarelto lawsuits. The plaintiffs involved are anxiously awaiting early 2017 bellwether trials as ordered by overseeing Judge Eldon Fallon. As time moves on, Xarelto lawsuits continue to grow in number.
At this time, Attorney Joseph Osborne is working to help other patients who feel that they have been negatively affected by Xarelto. He hopes to ensure that these patients are provided with an opportunity to evaluate their legal rights in the matter, and indicates that they could be entitled to substantial compensation. To better help those looking to learn more about their legal options, Attorney Osborne is offering free legal consultations to qualified individuals at this time.
To request additional Xarelto lawsuit information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2913147
-
Family Of Alabama Woman Files Xarelto Wrongful Death Lawsuit
Apr 25, 2016 | Righting Injustice
By Jennifer Walker-Journey
The family of an Alabama woman is suing Johnson & Johnson’s Janssen Pharmaceuticals and Bayer Healthcare, and their related companies, over claimsthat the companies’ blood thinner Xarelto caused injuries that contributed to her death.
Clarence E. Perkins, on behalf of the estate of Opal L. Perkins, filed the lawsuit in the U.S. District Court for the Eastern District of Louisiana, naming Janssen Research & Development, Jansen Ortho, Jansen Pharmaceuticals, Johnson & Johnson, Bayer Pharma, Bayer Corp, Bayer Healthcare Pharmaceuticals, Bayer Healthcare AG, and Bayer AG. The lawsuit alleges the companies fraudulently represented Xarelto to the medical and health care community.
The lawsuit claims that from September 2013 to April 2014, Opal Perkins was prescribed Xarelto to reduce the risk of developing pulmonary embolisms caused by her irregular heart rhythm condition known as atrial fibrillation. Around April 2014, the plaintiff began suffering from gastrointestinal bleeds, which caused her to become anemic, requiring a blood transfusion. The lawsuit claims that the severe and permanent personal injures she suffered led to her death.
The lawsuit blames the drug companies because they allegedly designed, researched, manufactured, tested, advertised, promoted, marketed, distributed and sold Xarelto while failing to properly investigate, research, and fully define the risks associated with the blood thinner. The lawsuit also claims that the companies did not warn medical professionals that there was no effective way to reverse the bleeding effects of Xarelto in the event of ableeding emergency.
Perkins’ lawsuit is one of hundreds waged against the drug companies over failure to warnclaims.
http://www.rightinginjustice.com/news/2016/04/25/family-of-alabama-woman-files-xarelto-wrongful-death-lawsuit/
-
Apr 26, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on an ongoing investigation conducted by European regulators concerning the results of Xarelto clinical trials. The investigation comes after increasing controversial claims surrounding the new-generation blood thinner, and its 2011 approval by the U.S. Food and Drug Administration. Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals are also facing thousands of lawsuits concerning the drug at this time, involving plaintiffs from across the nation who similarly allege that use of the anticoagulant drug can place patients at increased risk for the development of severe and dangerous bleeding events.
The clinical trial which is currently under investigation was conducted at the Duke Institute for Clinical Research in Durham, North Carolina. Detailed information sourced from the Project on Government Oversight shows that the issuing official who provided the U.S. Food and Drug Administration’s 2011 approval of Xarelto has actually expressed concerns over the decision. POGO noted, “The FDA approved Xarelto in 2011 over the objections of the primary FDA scientists assigned to study its safety and effectiveness. The report by the reviewers argued that patients could be ‘at greater risk of harm from stroke and/or bleeding’ if they took Xarelto than if they were treated skillfully with Warfarin, a blood thinner that has been on the market since the 1950’s.”
POGO also stated, “The official who issued the FDA’s decision to approve the drug expressed a series of misgivings about it.” They name this official as FDA Deputy Division Director Stephen M. Grant, and note that in a November 2011 memo, the official commented, “The decision was made difficult by the limitations in the design and conduct” [of the clinical trial].
At this time, Xarelto has become the topic of over 3,400 lawsuits which have been formed into two major groupings. Lawsuits filed in federal court, which now number over 2,800 have been consolidated and transferred to a single court in the Eastern District of Louisiana, forming MDL number 2592. These cases are being overseen by Judge Eldon Fallon, and continue to rise in number. They are also joined by over 620 other Xarelto lawsuits which have been consolidated by the Court of Common Pleas in Philadelphia, Pennsylvania, forming a mass tort program.
The European investigation into Xarelto clinical trials was additionally discussed by AllGov.org, which reported, “The clinical trial relied on blood testing devices that were the subject of two FDA warning letters before the trial began and an FDA recall notice after the trial ended, according to the Project on Government Oversight (POGO). Certain devices in the INRatio product line, the warning notice read, could deliver false test results and that use of those devices may “cause severe or life-threatening injuries, including death.”
Recent information concerning the investigation shows only that the European Medicines Agency, “is currently investigating whether the data generated from the INRatio device could have had any impact on the trial results and the extent of this impact, if applicable.” POGO also noted that an FDA staff review of the trial showed that results seemed to be biased in favor of Xarelto. As the investigations continue and those involved await new information, plaintiffs anxiously await their trial dates.
At this time, Attorney Joseph Osborne is working to help others who may be able to join the current lawsuit filings. Those who have used Xarelto and feel that they have been negatively affected by the drug may be eligible for significant compensation. They are greatly encouraged to take the opportunity to explore their legal rights in the matter. For those who are looking to further investigate their legal options, Attorney Osborne is currently offering complimentary consultations to qualified parties.
To request additional Xarelto bleeding lawsuit information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.keyc.com/story/31824888/xarelto-lawsuit-plaintiffs-await-results-of-european-regulator-investigation-into-xarelto-clinical-trial-results
-
Xarelto Lawsuit Filing Numbers Reportedly Rising In Both United States And Canada
Apr 26, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on Xarelto lawsuit filings, which have been regularly growing in number across the United States and Canada. Reports state that a lawsuit referencing Xarelto had been filed last February in Calgary, Canada and that another lawsuit filing is anticipated in Ontario. Plaintiffs in the U.S. have indicated that seeing the filings in Canada as well help to cement their allegations and prove that Canadian patients are also claiming that the drug can place users at increased risk for severe bleeding episodes.
On February 13, 2015, the Calgary Sun indicated that the head plaintiff in the Calgary Canadian class action lawsuit had come dangerously close to having a heart attack when she suffered from a sudden internal bleeding episode while using Xarelto. The woman’s lawsuit allegations state, “The health care professionals who were treating [her] for this hemorrhaging had considerable difficulty in stopping her bleeding.” And that, “They advised her that Xarelto was the cause of her hemorrhaging and that, unlike other anticoagulants such as warfarin, there was no way to reverse the anticoagulant effects of Xarelto.”
Xarelto gained FDA approval in 2011 in the U.S. and was released to the market without any corresponding antidote. It remained this way for several years, during which time Xarelto patients who endured even minor bleeding injuries could easily find themselves suffering from uncontrollable bleeding episodes. Due to the lack of antidote, it was very difficult for doctors to reverse the blood thinner’s effects and clot patients’ blood. Traditional blood thinners did not present patients with the same problem, as they have an available antidote through vitamin K. Patients using traditional blood thinners, therefore, who become injured and bleed, are able to be treated with vitamin K which will reverse the blood thinner’s effects and allow their blood to clot much quicker.
Reports surrounding Xarelto bleeding events show that as of last February, Health Canada (the Canadian equivalent of the U.S. Food and Drug Administration) had received nearly 1,100 reports of adverse health events among patients taking the blood thinner. The Xarelto class action lawsuit from Calgary refers to these reports by stating, “A dozen of those adverse events registered with Health Canada indicated that death had resulted from Xarelto.”
Plaintiffs from both Canada and the United States seem to share striking allegations against the drug and drug manufacturers, and unanimously note that if they had been made aware of the potential dangers that they now associate with the blood thinner, they would have been sure to use an alternative drug.
Attorneys across the board expect Canada and U.S. Xarelto lawsuit numbers to continue their steady growth as time goes on. In the meantime, Attorney Joseph Osborne is working to help other patients in the U.S. who have taken Xarelto and who feel that it has negatively impacted their well-being. Those who believe they have been affected by Xarelto could be entitled to substantial compensation, so it is important that these individuals be provided with an opportunity to investigate their legal rights completely. To better help those interested in exploring their legal options further, Attorney Osborne is offering complimentary legal consultations to qualified individuals at this time.
To request more information, or to ask questions, please contact Attorney Joseph Osborne by calling (866) 425-8902.
http://www.12newsnow.com/story/31824890/xarelto-lawsuit-filing-numbers-reportedly-rising-in-both-united-states-and-canada
-
Apr 26, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com comments on reports from Reuters with more details on current Xarelto lawsuits. Currently, it has been indicated that both U.S. and European drug regulators are investigating to determine whether a defective blood clotting medical device used during Xarelto clinical trials could have impacted the outcome of the results gathered. It has been indicated that the results may have been impacted in Xarelto’s favor, and could have led to a premature FDA-approval of the new-generation blood thinner, manufactured by Bayer AG and Johnson & Johnson subsidiary Janssen Pharmaceuticals.
Since its release in 2011, Xarelto has become the topic of more than 3,400 lawsuit filings. The plaintiffs filing the complaints share strikingly similar allegations that use of the blood thinner places patients at increased risk of the development of severe and dangerous bleeding episodes. Lawsuits referencing Xarelto have been formed into two major groupings: over 2,800 cases which were federally-filed have been transferred and consolidated to form MDL number 2592 in Eastern Louisiana. These lawsuits are joined by another group of over 620 complaints which were formed into a mass tort program in Philadelphia, Pennsylvania by the Court of Common Pleas.
The clinical study in question was conducted with the purpose of comparing new-generation Xarelto to a traditional blood thinner (warfarin) in terms of overall effectiveness for preventing strokes among those suffering from atrial fibrillation. It has been learned, however, that the study results could have been affected due to a defect in one of the medical devices used.
The European Medicines Agency commented on this possibility, stating, “Due to the defect, it is now thought that the INR (international normalized ration) device may have impacted the clotting results in some patients in the warfarin group.” They also stated that the study’s results would be published following the completion of their new investigation into this device. INR devices are used to measure how quickly blood is able to clot. It was reported that the system used to conduct this study had been recalled in December 2014 after researchers noted some significantly low results which were deemed false.
As the involved plaintiffs anxiously await trial dates, Attorney Joseph Osborne is working to assist other patients who have taken Xarelto and who feel that the blood-thinning drug negatively impacted their health in some way. He wants to help ensure that all affected patients will be provided with the important opportunity to investigate their legal rights in full. Affected parties could be entitled to significant compensation gained through legal action. To better assist those wishing to further explore their legal options, Attorney Osborne is now offering free legal consultations to qualified parties.
To request additional Xarelto bleeding lawsuit information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2916297
-
Xarelto Lawsuit Plaintiff Alleges That Anticoagulant Caused Life-Threatening Internal Bleed
Apr 27, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of a lawsuit which has been filed against Xarelto manufacturers Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) and Bayer Healthcare. The complaint was initially filed in the Eastern District of New York under case number 1:14-cv-04524. It was filed by a plaintiff from Texas who claims that new-generation blood thinner Xarelto’s manufacturers neglected to inform consumers and medical professionals of the dangerous side effects which she now links to use of their drug.
Further lawsuit details indicate that the plaintiff was prescribed Xarelto by her doctor to prevent the risk of stroke which is commonly associated with her atrial fibrillation condition. The plaintiff reports that she had taken Xarelto for only 5 months before she suddenly suffered from a life-threatening internal bleed. She says the bleed has left her with long-term medical needs, and therefore continued medical bills.
Just five years ago in 2011, Xarelto gained approval from the U.S. Food and Drug Administration. The drug was intended to treat patients who were recovering from hip and knee replacement surgeries as well as those who were suffering from pulmonary embolism and deep vein thrombosis. The drug’s approved uses were later expanded to include treatment for those with atrial fibrillation. Since the initial approval, the anticoagulant has also been given two “black box” warnings from the FDA. These are the most strict warnings a product can be given before being removed from the market and from public sale.
Today, Xarelto lawsuits are mounting and reportedly number over 3,400. The plaintiffs involved in the filings share similar allegations that the drug places users at increased risk for the development of dangerous and sudden bleeding episodes. More than 2,800 federally-filed Xarelto lawsuit cases have been consolidated and transferred to a single court in Eastern Louisiana by the JPML, forming MDL 2592. Additionally, over 620 Xarelto lawsuits have been formed into a mass tort program in Philadelphia, Pennsylvania by the Court of Common Pleas.
As the plaintiffs involved anxiously await trial dates, Attorney Joseph Osborne is working to help other patients who have used Xarelto and who believe that the drug has negatively impacted their health. Those who believe they have been affected are greatly encouraged to take advantage of the opportunity to explore their legal rights in the matter, as they may be entitled to significant compensation gained through legal action. To assist those who wish to further investigate their options at this time, Attorney Osborne is offering free legal consultations for qualified parties.
To request additional Xarelto lawsuit information, or to ask questions, please contact Attorney Joseph Osborne by calling (866) 425-8902.
http://www.kcentv.com/story/31835585/xarelto-lawsuit-plaintiff-alleges-that-anticoagulant-caused-life-threatening-internal-bleed
-
Apr 27, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of a lawsuit which has been filed against Bayer Healthcare and Janssen Pharmaceuticals (a subsidiary of parent company Johnson & Johnson). The lawsuit discusses Xarelto the new-generation, blood-thinning drug they manufacture. It was filed by a married couple from Ohio who together claim that the use of the anticoagulant caused the wife to endure a life-threatening internal bleed. The couple is seeking more than $150,000 in compensation to assist with current and future medical bills, as they note that the side effects from the bleed continue to impact the woman today, and will require medical care for a long-term period of time.
Additional details from the couple’s lawsuit note that the plaintiff used Xarelto (rivaroxaban) after being given a prescription for the drug by a doctor in order to treat her atrial fibrillation. Atrial fibrillation is a common heart condition which can place patients at heightened risk for the occurrence of strokes. The plaintiff and her husband report that just two months after starting to take the drug, the wife unexpectedly developed a serious gastrointestinal bleed and anemia, as well as several other injuries which were not specified in reports.
Xarelto gained approval by the FDA in 2011 in order to treat patients recovering from knee or hip replacement surgeries in addition to those suffering from deep vein thrombosis, pulmonary embolism, and atrial fibrillation. Since this approval five years ago, however, the blood thinner has received two “black box” warnings from the FDA which are the most severe product warnings possible to be given before a product is fully removed from the market.
The Ohio plaintiffs are joined by thousands of other plaintiffs from across the nation who have filed their own lawsuits and made strikingly similar claims in reference to the drug. In five year’s time, Xarelto has become the subject of over 3,400 lawsuits filed by plaintiffs from across the United States. These plaintiffs claim that use of the anticoagulant puts patients at heightened risk for the development of severe bleeding events, some of which have reportedly been fatal. Plaintiffs also agree that manufacturers Bayer and Janssen neglected to adequately inform the public and physicians of the substantial dangers linked to their drug, which reportedly brought in billions of dollars for the corporations.
At this time, Attorney Joseph Osborne is working to help other patients who have used Xarelto and who believe that the blood thinner caused them to suffer from adverse events. Those affected may be entitled to substantial compensation gained through legal action, and are encouraged to evaluate their legal options in the matter. To better assist those wishing to further investigate their legal rights, Attorney Osborne is offering complimentary legal consultations for qualified parties at this time.
To request more information on Xarelto bleeding lawsuits, or to ask questions, please contact Joseph Osborne, Esq., by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2917410
-
Apr 27, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com comments on a recent news release from Business Insider which indicated that NBA-All Star Chris Bosh of the Miami Heat is now struggling with another blood clot scare. Details regarding his current condition and specifics of his future basketball career plans have yet to be released, and as the article noted, “no determination will be made about his playing status until he goes through more tests and evaluation.” This information was attributed to ‘a person with knowledge’.
Bosh has unfortunately been sidelined with blood clot scares before. As Miami’s leading scorer, many follow his health troubles and await his safe return to the court. It was reported that Bosh was pulled from both the All-Star Game and 3-point contest because of what was first described as a ‘calf strain’. According to the article, last season the player “...was shut down at the All-Star break...because a blood clot had found its way to one of his lungs, and that issue is something that Bosh believes started as a calf problem.”
Blood clots in the lungs can cause pulmonary embolism, a dangerous and potentially fatal condition. After dealing with his first blood clot scare, Bosh joined with Xarelto manufacturer Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation) and began to do commercials for the anticoagulant drug. It was reported that he began to use the blood thinner at this time for a period of several months.
Xarelto and manufacturers Janssen and Bayer AG have been subjects of great controversy recently as well, as lawsuits surrounding the drug now number over 3,400. These lawsuits have been formed into two main groups with over 2,800 formed into a multidistrict litigation group (MDL 2592) in Eastern Louisiana, and over 620 Xarelto lawsuits now consolidated by the Court of Common Pleas in Philadelphia, Pennsylvania to form a mass tort program. Plaintiffs involved in each of these lawsuits share strikingly similar allegations that Xarelto puts users at increased risk of sudden and dangerous bleeding events, which in some cases proved fatal.
At this time, Attorney Joseph Osborne is working to help other patients who have taken Xarelto and who feel that they have been negatively impacted by the drug. He wants to ensure that all affected patients will be given the opportunity to fully evaluate their legal rights in the matter, as they may be entitled to substantial compensation. To assist those wanting to further investigate their options at this time, Attorney Osborne is offering free legal consultations to affected parties.
To request more Xarelto lawsuit information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2918345
-
Xarelto Lawsuit Plaintiffs Allege 4 Years Without An Available Antidote Is Negligent
Apr 26, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com comments on a common point of concern for plaintiffs involved in Xarelto bleeding lawsuits. Thousands of plaintiffs who have filed suit against the new-generation anticoagulant allege that the drug’s manufacturers, Bayer AG, and Janssen Pharmaceuticals showed severe negligence by neglecting to release the blood thinner to market with a corresponding antidote.
Xarelto was released in 2011 after approval by the U.S. Food and Drug Administration. It was approved to treat patients suffering from deep vein thrombosis, pulmonary embolism, or atrial fibrillation, as well as those who are recovering from hip and knee replacement surgeries. The drug was initially popular, as it provides users with freedoms other blood thinners had been unable to.
After many lawsuits surrounding the drug began to add up, however, many became concerned about the blood thinner’s lack of antidote, stating that it was a major issue. Because Xarelto went years without an available antidote, patients taking it who had suffered even minor injuries were reportedly in danger of significant bleeds which could become uncontrollable and even fatal. Those taking Xarelto who became injured would be unable to be treated with an antidote by their physicians.
Traditional blood thinners, quite differently, were released to the market with an available antidote in vitamin K. Patients taking these blood thinners, therefore, who become injured and are bleeding are able to be treated with vitamin K by their physicians. This treatment will counter the effects of the blood thinner and will allow the patient’s blood to clot.
Today, lawsuits surrounding Xarelto have surpassed 3,400 in number. They have been formed into two major groupings: over 620 cases were consolidated in Philadelphia, Pennsylvania by the Court of Common Pleas forming a Mass Tort Program while more than 2,800 others cases have been transferred to a single court in Eastern Louisiana forming MDL Number 2592. Plaintiffs involved in these cases commonly allege that Xarelto use puts patients at increased risk for the development of severe and even fatal bleeding events.
As those involved anxiously await trial, Attorney Joseph Osborne is currently looking to help others who have taken the drug and who believe that it has caused them to suffer from health problems. He wants to help ensure that affected patients will be given the opportunity to fully evaluate their legal rights in the matter, as they may be entitled to substantial compensation. To better assist those who need it, Attorney Osborne is now offering complimentary legal consultations to qualified parties.
To ask questions or request further information concerning Xarelto litigation, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2914910
-
Apr 29, 2016 | Top Class Actions
By Tamara Burns
Xarelto (rivaroxaban) is a medication used to prevent clots in the blood, otherwise known as an anticoagulant or blood thinner. It has been on the market since 2008 and is manufactured by Bayer.
As with any over-the-counter or prescription medication, side effects are common with the use of drugs. Many times the side effects are mild and may wane and disappear once the body adjusts to the medication. In other cases, the side effects experienced by patients can be severe – or even fatal.
Xarelto Side Effects
With Xarelto, the following side effects are common and are usually mild in nature, and may reduce or disappear with continued use:
Itching
Back pain
Headache
Pain in the extremities
Muscle pain or spasm
Lightheadedness or fainting
One of the most dangerous Xarelto side effects is internal bleeding. Because Xarelto’s method of action involves the drug inhibiting the body’s natural clotting mechanism, any patient can be at risk for increased internal bleeding. A patient may have had no issues with bruising or internal bleeding in the past, but may experience these Xarelto problems on the medication.
Internal bleeding may be difficult to determine at first since the site of the bleeding cannot be visualized. Most often, internal bleeding as a result of Xarelto side effects is located in the gastrointestinal tract or in the brain.
The following signs and symptoms indicate the possibility of internal bleeding Xarelto side effects:
Red, black or tarry stools
Vomiting up a substance that resembles coffee grounds
Red or dark brown urine
Bruising
Unusual pain
Confusion
Dizziness
Low blood pressure
Weakness
Loss of coordination or balance
Vision difficulties
Slurring of speech
Extreme sleepiness or loss of consciousness
With an older anticoagulant drug that was a staple for six decades, warfarin, there was an antidote to reverse bleeding. Patients could have fresh frozen plasma and intravenous vitamin K administered to stop the bleed.
However, with Xarelto, there is no antidote, and if the bleeding is too severe despite emergency intervention, the bleeding can be fatal.
Xarelto Internal Bleeding Lawsuits
Lawsuits against Xarelto’s manufacturer, Bayer, are so numerous that they have all been consolidated into a multidistrict litigation (MDL) to address the allegations.
In an MDL, the lawsuits are all set to a single court under a single judge so that pretrial discovery may be streamlined. A small group of cases are then selected as “bellwether” cases to represent the group to see how the proceedings will play out.
Such a process allows for non-duplicative discovery and allows the cases to have similar rulings and outcomes.
In the Xarelto MDL, there are over 3,000 cases currently pending in the U.S. District Court for the Eastern District of Louisiana with trials set to begin in August of this year.
These lawsuits generally allege that Bayer negligently and fraudulently misrepresented the product, breached warranties, and violated consumer protection laws and seek damages for medical expenses, loss of spousal companionship, lost wages and earning capacity and more.
If you or someone you loved experienced internal bleeding Xarelto side effects or other Xarelto problems, you may be eligible to file a lawsuit. An experienced Xarelto attorney can review your case at no charge and can explain your legal options to you.
https://topclassactions.com/lawsuit-settlements/lawsuit-news/333832-xarelto-risk-bleeding/
-
Apr 22, 2016 | ClassAction.com
Xarelto Lawsuit
Approved by the U.S. Food and Drug Administration (FDA) in 2011, Xarelto is indicated to reduce the risk of strokes, deep vein thrombosis (DVT), pulmonary embolism (PE), and blood clots.
Xarelto has been promoted as superior to older types of blood thinners but may in fact be more dangerous because, unlike older products, it can cause bleeding that cannot be stopped, even by a doctor.
The legal team at ClassAction.com is filing lawsuits on behalf of injures Xarelto users and their loved ones.
Serious Adverse Xarelto Side Effects
Like other anticoagulant drugs, Xarelto carries a risk of internal bleeding (hemorrhaging) side effects. But Xarelto—marketed as a superior alternative to traditional blood thinners such as warfarin—is different from earlier anticoagulants in important ways. First, it does not have an antidote to stop internal bleeding side effects. Second, it does not require regular blood monitoring tests that may help prevent uncontrolled bleeding.
Xarelto users have claimed that they suffered the following serious side effects while taking the drug as directed:
Intracranial hemorrhages
Abdominal hemorrhages
Retinal hemorrhages
Wound infection and complication
Epidural hematoma
Adrenal bleeding
Excessive blood loss
Stroke
Death
Learn more about Xarelto side effects, scientific research, FDA warnings, and more on our Xarelto Product Information Page.
HAS THERE BEEN A XARELTO RECALL?
Xarelto has not been recalled. Doctors are still prescribing the drug to patients despite its potential to cause harm.
FDA safety information for Xarelto can be found here. It’s worth noting that some FDA scientists had misgivings about approving Xarelto due to a perceived lack of care in clinical trial design. FDA reviewers concluded that patients could be put at greater risk of harm from stroke and/or bleeding when treated with Xarelto, compared to careful treatment with warfarin. In one Xarelto clinical trial, 30-days after the study ended Xarelto subjects had experienced 22 strokes while warfarin users had experienced 6 strokes.
DRUGS AFFECTED
U.S. patients may have been prescribed the following Xarelto oral dosages:
15 mg
20 mg
10 mg
XARELTO LIABILITY
Specific allegations include claims that the drug presents an unreasonable risk of injury and that its labeling does not adequately warn about its potential side effects.
Claimants also allege that Xarelto’s lack of an antidote constitutes a design defect and that the drug does not provide greater patient benefits than drugs like warfarin, which were safely administered for decades.
Some believe that Janssen/Bayer intentionally concealed knowledge of Xarelto’s irreversible, life-threatening bleeding.
SIMILAR LAWSUITS
Xarelto lawsuits are similar to lawsuits over Pradaxa, another newer-generation anticoagulant. Thousands of Pradaxa lawsuits were filed and consolidated in federal court, and millions of dollars in compensation were awarded to victims.
Like Xarelto, Pradaxa (made by Boehringer Ingelheim) is marketed as superior to warfarin. Also like Xarelto, Pradaxa does not have an antidote to stop dangerous bleeding events and is marketed as being easier to use than warfarin.
Pradaxa, which gained FDA approval in 2010, led all drugs in FDA reported adverse events in 2011 (3,781 events overall, including 542 patient deaths, 2,367 hemorrhage reports, and 644 stroke reports).
Widespread patient harm from Pradaxa led to about 4,000 lawsuits being filed as part of a multidistrict litigation (MDL). The MDL settled in 2014 for $650 million.
Xarelto and Pradaxa are different drugs, and there is no guarantee that Xarelto litigation will go the way of Pradaxa lawsuits. Still, given the similarity of the drugs and their side effects, the Pradaxa settlement should be encouraging to Xarelto victims who are currently seeking compensation.
XARELTO MASS TORT LAWSUIT
ClassAction.com attorneys have filed a Xarelto MDL lawsuit on behalf of injured clients. Plaintiffs will maintain their own lawyer and their own trial. The first trials in this case will begin in Fall 2016. More than 1,700 separate claims are contained in the MDL.
It is not too late to join the Xarelto MDL, but the time to file a claim is limited.
LAWSUIT ELIGIBILITY
Patients who took Xarelto as indicated and suffered a major bleeding event, stroke, or death could be eligible for legal action against the drug’s manufacturers. Also potentially eligible are the family members of a patient who died while taking Xarelto.
Individual eligibility can be determined by speaking with our legal team.
HOW A LAWSUIT CAN HELP
A Xarelto lawsuit settlement can provide money to injured users who suffered financial losses (such as medical bills and lost wages) as well as non-financial losses (pain and suffering) caused by a Xarelto injury. Compensation may also be available for the survivors of Xarelto patients who suffered fatal bleeding events or strokes.
DO I NEED A LAWYER?
A lawyer is not necessary to file a lawsuit, but without experienced legal representation litigants risk not receiving a fair amount of compensation for their losses.
Drug manufacturers are among the most profitable companies in the world and hire top-notch defense attorneys to minimize their liability for product-related injuries. In 2014, Xarelto brought in $1.5 billion in U.S. sales. Such profits make it possible for drug companies to thwart the efforts of everyday people seeking justice through the courts.
Working with an experienced injury attorney levels the playing field and gives plaintiffs the best chance at a favorable recovery.
WHAT TO DO IF YOU ARE AFFECTED
If you or a loved one took Xarelto and experienced bleeding complications, it’s in your best interest to speak with our legal team as soon as possible. Failure to take prompt action could mean that the statute of limitations expires, leaving you with no legal recourse.
https://www.classaction.com/xarelto/lawsuit/
-
Week Adjourned: 4.22.16 – Xarelto, Natural Sunscreen, NFL Concussions
Apr 22, 2016 | LawyersandSettlements.com
By Lucy C
Xarelto Lawsuits Head North. Bayer Inc, is facing a Xarelto class action lawsuit filed in Canada—in Calgary to be precise—alleging its blood thinner is linked to dozens of deaths. The lead plaintiff in this class action alleges that the anticoagulant drug caused her to suffer from an uncontrollable bleeding event which nearly led her to cardiac arrest. Sadly, this lawsuit has a familiar ring to it.
According to reports published in the Calgary Sun, as of March 2015, Health Canada had received an estimated 1,100 adverse event reports from patients taking Xarelto. The article indicates that, according to a lawyer from Toronto, if the class action is successful, “…it would be in the millions of dollars.” The Calgary Sun report also discussed the likely formation of another class action suit in Ontario at this time.
This Canadian Xarelto class action lawsuit closely follows the formation of Multidistrict Litigation number 2592 in the United States by the U.S. Judicial Panel on Multidistrict Litigation. This MDL consolidated and transferred over 2,800 lawsuits filed in reference to Xarelto by plaintiffs who allege much the same. These lawsuits are additionally joined by another group of 620 Xarelto lawsuits which have been formed into a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania. Lawsuits in these groupings have been filed against defendant Bayer AG as well as Janssen Pharmaceuticals, a subdivision of Johnson & Johnson corporation.
Not in our Nature? Where would we be without our weekly dose of consumer fraud litigation? This week, it’s Sunology Natural Sun Protection who is facing a consumer fraud class action lawsuit. The allegations are that the advertising of its sunscreen products is misleading to the consumer.
Filed by Vivian Douek, individually and for all others similarly situated, the Sunology Natural Sun complaint alleges the defendant, McNabb LLC, doing business as Sunology Natural Sun Protection, markets and advertises certain of its SPF 50 sunscreens as containing “active ingredients derived from nature”, and therefore these products are “natural.”
However, the plaintiffs contend that these products in fact contain various artificial and synthetic ingredients. Consequently, consumers paid a premium for products the defendant misrepresented, according to the complaint.
Therefore, the lawsuit states that the defendant is in violation of New York General Business Law and consumer protection statutes in every state, violation of the Magnuson-Moss Warranty Act, breach of express and implied warranties, unjust enrichment and negligent misrepresentation.
https://www.lawyersandsettlements.com/blog/week-adjourned-4-22-16-xarelto-natural-sunscreen-nfl-concussions.html
-
Xarelto Litigation Scheduling Order Sets Injury Cases in Motion
Apr 25, 2016 | Lieff Cabraser Heimann & Bernstein
By Lieff Cabraser
On April 21, 2016, Judge Eldon E. Fallon, the federal judge supervising and overseeing the centralized litigation against Janssen, Johnson & Johnson and Bayer over Xarelto, issued an order scheduling the depositions of plaintiffs and defense witnesses. The court is overseeing the discovery necessary to develop several “bellwether” trials in order to evaluate the strength and weaknesses of the cases brought against the pharmaceutical giants and to determine the values of certain harms and injuries.
The depositions of the plaintiffs selected will take place in the federal courts near where the claimants live. The Court set the order of the depositions: plaintiff, prescribing doctor, treating doctor, and the sales representative who “detailed” the doctor, to be deposed where the depositions can fit in. The Court is determined to move these serious and complicated cases forward as expeditiously and efficiently as possible.Contact Lieff Cabraser
Lieff Cabraser represents injured patients prescribed Xarelto in lawsuits charging Xarelto is a dangerous and defective drug because in some patients it triggers irreversible uncontrolled bleeding and other life-threatening complications. Xarelto (rivaroxaban) is sold in the U.S. by Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson (“J&J”). Our law firm has been recognized by U.S. News, Best Lawyers, and The National Law Journal as one of the top plaintiffs’ law firms in the nation. Please call us toll-free at 1 888-321-1510 or contact us by completing our online contact form.Xarelto Drug and Injury Lawsuits Timeline
Read a timeline charting Xarelto’s release through reports of injuries and Xarelto lawsuits.
http://www.lieffcabraser.com/2016/04/xarelto-litigation-scheduling-order-sets-cases-in-motion/
-
California Man Blames Xarelto for Subdural Hematoma
Apr 26, 2016 | The Legal Examiner
By Kendra Goldhirsch
In December 2014, all federally filed Xarelto lawsuits were consolidated into the Eastern District of Louisiana for pre-trial proceedings. Since then, the court has seen a steady increase in the number of cases there.
Another new lawsuit joined the MDL on March 16, 2016. The plaintiff is a resident of California, and claims that after using Xarelto, he suffered serious injuries. He seeks damages in excess of $75,000.Plaintiff Suffers Subdural Hematoma After Taking Xarelto
According to his complaint, the plaintiff started using Xarelto in July 2013, to reduce the risk of stroke associated with atrial fibrillation. The FDA approved Xarelto for this use in November 2011. A so-called “new-generation” blood thinner, the drug help is intended to help to reduce the risk of blood clots.
The plaintiff continued to use the drug until about April 2014. At that time, he claims he suffered life-threatening bleeding and subdural hematoma, causing severe and permanent physical injuries. A subdural hematoma is a type of brain hemorrhage that occurs when the blood vessels rupture between the brain and the other membrane layers that cover it. The resulting blood can build up in this area and compress the brain tissue. It’s a serious condition that can cause loss of consciousness, brain damage, and even death in some cases.
The plaintiff blames manufacturers Janssen Pharmaceuticals, parent company Johnson & Johnson (J&J), and Bayer AG for failing to provide adequate warnings concerning the risks of excessive bleeding.Plaintiff Points Out Ways that Manufacturers Downplayed Risks
The plaintiff claims that approval for Xarelto for reducing the risk of stroke in patients with non-valvular atrial fibrillation was based on a clinical study known as the “ROCKET AF” trial. The study’s findings showed that Xarelto (rivaroxaban) was similar to warfarin—the leading anticoagulant for decades—for the prevention of stroke in this population, with a similar risk of major bleeding. But researchers noted that gastrointestinal bleeding occurred more frequently in those participants taking Xarelto.
According to the plaintiff, manufacturers used the results in their marketing materials, but failed to highlight this increased risk of gastrointestinal bleeding. They also advertised Xarelto as being a more convenient alternative to warfarin, since it didn’t require regular blood monitoring or dietary changes, and since it came in an easy once-a-day dose. The plaintiff notes that even in the FDA review process, however, some reviewers questioned the wisdom of this dose, stating that blood levels studies had shown peaks and troughs that could be eliminated by twice-daily dosing.
Finally, the plaintiff alleges that unlike warfarin, Xarelto has no readily available antidote to treat excessive bleeding. Whereas patients taking warfarin can be treated with injections of vitamin K to encourage blood to clot, patients taking Xarelto have no such solution. That means they must simply wait it out while the body gradually metabolizes the drug—which can make excessive bleeding potentially much more dangerous and even deadly.
There was no warning on the label alerting physicians to this important risk, the plaintiff asserts. He brings counts of negligence, strict products liability, breach of warranties, fraudulent misrepresentation and concealment, negligent misrepresentation, fraud and deceit. He further asserts that, had he known about the true facts with respect to the dangerous safety concerns associated with Xarelto, he says he never would have used the drug.
http://newyork.legalexaminer.com/defective-dangerous-products/california-man-blames-xarelto-for-subdural-hematoma/
-
More Than 4,500 Xarelto Lawsuits Consolidated
Apr 27, 2016 | LawyersandSettlements.com
By Heidi Turner
The number of Xarelto lawsuits consolidated for pretrial proceedings sits at more than 4,500, and a lawsuit alleging patients suffered from Xarelto side effects has now been filed in Canada. Meanwhile, the New York Times(3/1/16) reports that some researchers are concerned about data apparently left out of a vital Xarelto study. Whether more Xarelto lawsuits are on the way remains to be seen.
Xarelto is an anticoagulant medication used to reduce the risk of blood clots and strokes. The drug has been linked to an increased risk of uncontrollable bleeding, a frequent side effect in anticoagulant medications. However, whereas an older anticoagulant - Warfarin - has an antidote, Xarelto has no commonly accepted antidote to stop uncontrolled bleeding events.
Patients and their loved ones have filed lawsuits against the makers of Xarelto, alleging they were not adequately warned about the risk of serious side effects, and suffered severe bleeding episodes as a result. According to court records, 4,579 lawsuits were consolidated for pretrial proceedings as of April 15, 2016 in MDL 2592. That’s up from 3,987 consolidated as of February 16, 2016.
And while lawsuits continue to be filed in the United States, Xarelto lawsuits are also being filed in Canada. Gordon Gibb, writing for LawyersandSettlements, notes one lawsuit was recently filed in Calgary, with the plaintiff alleging she nearly suffered a heart attack after taking Xarelto and developing internal bleeding. A lawsuit may also be filed in Ontario on behalf of the family of an 83-year-old woman who reportedly bled to death in her shower while on Xarelto therapy.Concerns have also been raised about the study that was used to approve Xarelto therapy. Xarelto was approved for the market based heavily on a trial called the ROCKET AF trial. That trial found that Xarelto (known generically as rivaroxaban) was at least as good as warfarin in preventing stroke and embolism, and superior to warfarin in decreasing the risk of bleeding in the brain and fatal bleeding events. But one of the tools used in the trial, the Alere INRatio Monitor System, was recalled in 2014 due to abnormal readings.
Those abnormal readings could have resulted in patients’ warfarin doses being unnecessarily increased, also increasing the risk of serious side effects. Although researchers wrote a letter to The New England Journal of Medicine defending the trial results, the New York Times (3/1/16) notes that plaintiffs’ attorneys argue that vital lab data was left out of that letter, making the researchers’ claims inaccurate.
While researchers and critics argue over the validity of the ROCKET AF trial findings, plaintiffs file lawsuits arguing they were never properly warned about the risk of side effects associated with Xarelto.https://www.lawyersandsettlements.com/articles/xarelto/xarelto-lawsuit-death-bleeding-issue-40-21437.html
-
Apr 27, 2016 | Isaacs & Isaacs
If you or somebody you love was injured from taking the anticoagulant Xarelto you need to talk to an Isaacs & Isaacs Xarelto Lawsuit lawyer immediately. We have a 99% success rate in winning fair and just compensation for our clients. We serve people in Kentucky, Indiana & Ohio. Call 800-800-8888 now to speak with an experienced Xarelto lawyer. Our team is standing by 24/7 to help folks who have been hurt by this dangerous drug.
What is Xarelto Used For?
Xarelto was developed by Janssen pharmaceutical, a division of Johnson & Johnson, as a blood thinner which could replace the commonly used blood thinner Warfarin. The advertised benefits of taking Xarelto are: No need for blood monitoring; No dietary restrictions; No frequent adjustments;
In 2011 the United States Food and Drug Administration (FDA) approved Xarelto to prevent Deep Vein Thrombosis for patients undergoing hip or knee replacement surgery. Later that year Xarelto gained FDA approval for stroke prevention in patients with Atrial Fibrillation (irregular heartbeat).
Xarelto Indications Include Treating:
Atrial Fibrillation (AFib – irregular heartbeat which could lead to stroke); Deep Vein Thrombosis (DVT – blood clot which forms in the leg & can travel to lungs); Pulmonary Embolism (PE – possibly fatal blood clots in the lung); Reduce the risk of blood clots after hip/knee replacement surgery.
Side Effects of Xarelto
According to the FDA label, dangerous side effects from Xarelto Blood Thinner can include: Forming a blood clot in the heart which can cause a stroke; Frequent nose bleeds; Bleeding gums; Heavy menstrual bleeding; Hemorrhaging; Red, pink, or brown urine; Bright red or tar-like black stools; Coughing up blood/blood clots; Vomiting blood; Headaches; Dizziness; Weakness; Infection at wound sites; Back pain; Numbness; Tingling; Incontinence; Spinal blood clot which can lead to paralysis.
The label warns to talk to your doctor immediately if you are experiencing any of the above side effects.
Are Xarelto Side Effects Controllable?
The FDA label warns patients not to stop taking the drug or miss a dose as this could prove dangerous. It warns against taking too much (double dosing) and of running out before getting the prescription refilled. Patients are warned not the take Xarelto if they have any kind of abnormal bleeding, and to talk to their doctor before taking Xarelto if they have ever had: Bleeding problems; Kidney or liver problems; Are pregnant/planning to become pregnant; Are breastfeeding.
The FDA label warns patients to tell doctors/ dentists before having any kind of surgery, medical, or dental procedure. Patients are warned not to take this medication if they take certain other medications, and if they are not sure if they should take Xarelto along with other current medications, including non-prescribed meds like aspirin, vitamins, and herbal remedies like St. John’s Wort, to ask their doctor first, before taking Xarelto.
Is There an Xarelto Antidote?
The main dangerous side effect of taking Xarelto is uncontrollable bleeding, and while Xarelto is vastly more expensive than the widely used blood thinner Warfarin which was the standard anticoagulant drug used since the 1950s, unlike Warfarin there’s no antidote for Xarelto if a patient begins to bleed out. Another dangerous side effect is that if you take Xarelto to prevent blood clots which could cause strokes and you quit taking Xarelto, you are at a much greater risk of forming the blood clots after you stop taking the drug.
Xarelto Lawsuits Continue to Mount
The first lawsuits were filed in 2014, three years after the drug gained FDA approval.
To date thousands of lawsuits have been brought against parent company Johnson & Johnson and its subsidiaries Bayer & Janssen Pharmaceutical. The lawsuits allege failure to warn patients of the dangers of taking this drug, and also that the drug itself is unreasonably dangerous because it can cause bleeding and there’s no antidote if the bleeding starts.Many of these cases are wrongful death suits brought by family members on behalf of decedents who died from uncontrolled bleeding after taking Xarelto, without being warned of the hazards the drug poses. When you take a drug that can cause uncontrolled bleeding and there is no antidote to stop the bleeding once it starts, it can be considered unreasonably dangerous.
Xarelto Settlements Can Depend on the Type of Lawsuit
The Xarelto lawsuit cases rapidly gained MultiDistrict Litigation (MDL) status to consolidate 2,800 of the cases filed and allow a federal district judge to rule on factual issues and pretrial motions. Currently these cases have not been tried or settled, but victims continue to file cases. Allegations vary, according to the facts of each case, but include: Strict Product Liability (SPL):Failure to warn; SPL: Design Defect; Negligence (N): Failure to Warn; N: Negligent Design; N: Negligent Misrepresentation; Breach of Warranty (BOW): Breach of Express Warranty; BOW: Breach of Implied Warranty; Fraud; Violation of Consumer Protection Laws; Wrongful Death; Punitive Damages (To punish wrongdoers and discourage similar behavior).
Civil litigation can take several years to settle or go to trial. Especially in mass tort actions where there may be millions of documents to go through and numerous motions to file before the trial or settlement negotiations even begin. Your attorney has little control over this process when there are thousands of cases against a defendant company such as a bad drug manufacturer.
Typically, after MDL issues are ruled on by the presiding federal judge, the cases are returned to the venues where they were filed for trial if no settlement has been reached. The stronger the evidence against the company, the more likely they will be to offer a large amount of money to settle. Trials are costly and can drag on through appeals, and nobody can predict how large an amount of money a jury may award a plaintiff who has been grievously injured by a big company’s negligence or wrongful act(s). Because of these factors most cases are settled, if the company is willing to offer plaintiffs a just sum to cover the damages they’ve suffered.How Xarelto Lawsuit Lawyers Can Help
If you or somebody you love have been injured from taking the drug Xarelto, or if you have lost a loved one who was on this drug and had a fatal incident of uncontrolled bleeding, you should talk to an Isaacs & Isaacs Xarelto lawsuit lawyer immediately. An experienced Xarelto attorney can help you to understand whether you have a case, and will handle the burden of the long, complicated, and costly litigation process so you can begin to heal.
Isaacs & Isaacs has a 99% success rate in successfully recovering fair and just settlements for our clients who have been injured in Kentucky, Indiana and Ohio. We have the resources and experience to fight this battle for you. We understand that if you have been seriously hurt or have recently lost a loved one you may have financial issues along with everything else, so you don’t have to pay us anything to file your case until we successfully obtain a fair and just settlement or judgment for your: Pain and suffering; Lost wages or future earnings; Disability and loss of future earning capacity; Medical bills, past, present and future; Funeral costs; Loss of the companionship and help your loved one provided; Possibly punitive damages(to punish wrongdoers and discourage similar behavior).
There’s a statute of limitations for filing a lawsuit, depending on the facts of your case, and sometimes the clock starts ticking the moment the injury occurs. Isaacs & Isaacs understands how crucial these filing deadlines are, and our experienced Xarelto lawsuit lawyers are on call around the clock to help you understand whether you have a case.
When You Call Isaacs & Isaacs Our Skilled Legal Team Will:
Listen to your story; Answer any questions you may have;Investigate the facts of your case; Obtain your medical records and other important evidence; Analyze the facts to determine which legal action(s) to file; Plan the best strategy to obtain a fair and just settlement or award of damages for your ordeal.
We will not leave you waiting and wondering during this painful time. In mass litigation, such as the thousands of Xarelto lawsuits people are filing around the country, things could drag on for as long as 3-4 years. We will keep you informed about how your case is progressing, answering your questions and maintaining communication about the progress of your case and any new developments.
When you and your loved ones have been injured by somebody’s negligence or wrongful act, the injury can permeate every corner of your life, including financial stress because you may not be able to work and the bills keep coming. We will represent you on a contingency fee basis. You don’t pay us anything until/ unless we win your case.
You can call us 24/7 at 800-800-8888 for a no-cost consultation and case evaluation. Don’t put it off any longer. We are here for you.
https://www.isaacsandisaacs.com/practice-areas/drugs/xarelto
Full Text of Stories Below
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Add recipients
Suggested